13 people evaluated, 4 hospitalized after carbon monoxide alarm in Ocean City, Maryland hotel
Ocean City building inspectors and gas company personnel are working to determine the source of the gas.
Ocean City Fire crews responded to the alarm at the Ashore Hotel at 10100 Coastal Highway around 11 a.m., officials said.
Additional EMS crews and resources were requested at the scene due to the number of people affected.
A total of 13 people were evaluated on the scene, and four were transported to hospitals due to elevated levels of carbon monoxide in their blood, according to officials.
This story will be updated as more information becomes available.
Carbon monoxide is a gas that, when inhaled, can lead to illness or death, according to the Centers for Disease Control and Prevention (CDC). Symptoms of carbon monoxide poisoning include dizziness, headache, vomiting and confusion. Some of the symptoms are similar to flu symptoms.
The odorless gas can be produced by burning furnaces, car exhaust, portable generators, charcoal grills and some other household appliances, the CDC said.
More than 400 people die from unintentional carbon monoxide poisoning each year in the U.S., according to the CDC.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21
OVERLAND PARK, Kan., August 07, 2025--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its fourth quarter and full year 2025 financial results before market open on Thursday, August 21, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (August 21, 2025) at 8:30 am ET to discuss the results. To register for this conference call, please use this link: After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website or via this link. About SelectQuote: Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care. With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select, which proactively connects consumers with a wide breadth of healthcare services supporting their needs. View source version on Contacts Investor Relations: Sloan Bohlen877-678-4083investorrelations@ Media: Matt Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Axios
2 minutes ago
- Axios
Vaccine opt-outs rise again among Arkansas kids
The rate of nonmedical exemptions for vaccines among Arkansas kindergartners saw a slight uptick in the 2024-25 school year, according to newly released data from the CDC. The big picture: Vaccination coverage among American kindergartners decreased for all reported vaccines during the 2024-2025 school year. The drop coincides with measles cases hitting a 33-year high in the U.S., while Trump's Health Department secretary, Robert F. Kennedy Jr., upends longstanding vaccine norms. By the numbers: About 3.5% of kindergartners in Arkansas had nonmedical exemptions for vaccines in the 2024-25 school year, up from 3.4% the year before. The rate has continuously been trending upward. Just 1.2% of Arkansas kindergartners had a nonmedical exemption in the 2014-15 school year, according to the CDC. Medical exemptions in the state have held steady at about 0.1%, meaning 99.9% of children do not have a medical reason for not getting vaccinated. Threat level: Roughly 92-94% of the population needs to be vaccinated against measles to avoid community spread, according to the American Academy of Pediatrics.
Medscape
2 minutes ago
- Medscape
Common Painkiller Tied to Heart Failure Risk in Older Adults
The antiseizure medication pregabalin, which is commonly prescribed for chronic pain, has been linked to an increased risk for heart failure (HF), particularly in those with a history of cardiovascular disease (CVD), new data suggested. In a cohort of more than 240,000 Medicare beneficiaries with noncancer chronic pain, initiation of pregabalin was associated with a 48% higher risk for new-onset HF overall and an 85% higher risk in those with a history of CVD than initiation of gabapentin. The study was published online on August 1 in JAMA Network Open . Widely Prescribed Medications Chronic pain affects up to 30% of adults aged 65 years or older. Nonopioid medications, such as the gabapentinoids pregabalin and gabapentin, are widely prescribed for chronic pain, the investigators, led by Elizabeth Park, MD, Columbia University Irving Medical Center in New York City, noted. Pregabalin has greater potency than gabapentin in binding to the α2δ subunit of the L-type calcium channel and therefore may be associated with an increased risk for HF through actions to cause sodium/water retention. To investigate further, investigators evaluated 246,237 Medicare beneficiaries between 2014 and 2018, including 18,622 (8%) new pregabalin users and 227,615 (92%) new gabapentin users. All patients were aged 65-89 years, had chronic noncancer pain, and had no history of HF. The researchers used inverse probability of treatment weighting to adjust for an extensive list of 231 covariates to reduce confounding and attempted to closely emulate a hypothetical target trial in which Medicare patients filled new prescriptions for pregabalin or gabapentin for noncancer pain. During 114,113 person-years of follow-up, 1470 patients had a hospital admission or emergency department visit for HF. The rate of HF per 1000 person-years was 18.2 for pregabalin and 12.5 — translating to roughly six additional HF events annually for every 1000 patients treated with pregabalin — with an adjusted hazard ratio (HR) of 1.48. The difference was even more pronounced in patients with a history of CVD, with an adjusted HR of 1.85. An increased risk for outpatient HF diagnoses was also seen (adjusted HR, 1.27), but there was no difference in all-cause mortality between groups. The authors said the findings further support current recommendations from the European Medicines Agency to exercise caution when prescribing pregabalin to older adults with CVD. The American Heart Association currently lists pregabalin, but not gabapentin, as a medication that may cause or exacerbate HF. Immediate Clinical Implications The co-authors of an invited commentary noted that the study provides 'timely and clinically relevant insights' into the cardiovascular safety of these two widely used gabapentinoids. From a clinical standpoint, the findings have 'immediate clinical implications,' wrote Robert Zhang, MD, with Weill Cornell Medicine, New York City, and Edo Birati, MD, Tzafon (Poriya) Medical Center, Poriya, Israel. For older adults with chronic pain, particularly those with CVD, 'clinicians should weigh the potential cardiovascular risks associated with pregabalin against its analgesic benefits. This is particularly relevant given the growing use of gabapentinoids in older populations and ongoing polypharmacy issues in this age group,' Zhang and Birati advised. 'Furthermore, if pregabalin use is associated with new-onset HF, it raises the possibility that the drug may unmask underlying subclinical cardiovascular disease, which suggests a need for careful cardiac evaluation prior to prescribing this medication,' they added. 'The study serves as an important reminder that not all gabapentinoids are created equal and that in the pursuit of safer pain control, vigilance for unintended harms remains paramount,' the investigators concluded.
